HRP20190405T1 - Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba - Google Patents

Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba

Info

Publication number
HRP20190405T1
HRP20190405T1 HRP20190405TT HRP20190405T HRP20190405T1 HR P20190405 T1 HRP20190405 T1 HR P20190405T1 HR P20190405T T HRP20190405T T HR P20190405TT HR P20190405 T HRP20190405 T HR P20190405T HR P20190405 T1 HRP20190405 T1 HR P20190405T1
Authority
HR
Croatia
Prior art keywords
benralizumab
asthma
methods
exacerbation rates
reducing exacerbation
Prior art date
Application number
HRP20190405TT
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20190405T1 publication Critical patent/HRP20190405T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190405TT 2013-08-12 2019-03-01 Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba HRP20190405T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
EP14835826.0A EP3033101B1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (1)

Publication Number Publication Date
HRP20190405T1 true HRP20190405T1 (hr) 2019-04-19

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190405TT HRP20190405T1 (hr) 2013-08-12 2019-03-01 Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba

Country Status (25)

Country Link
US (2) US9441037B2 (hr)
EP (1) EP3033101B1 (hr)
JP (3) JP6746495B2 (hr)
KR (2) KR20220057637A (hr)
CN (2) CN111588848A (hr)
AU (2) AU2014306956B2 (hr)
BR (1) BR112016002401A8 (hr)
CA (1) CA2918105C (hr)
CY (1) CY1122132T1 (hr)
DK (1) DK3033101T3 (hr)
ES (1) ES2716906T3 (hr)
HK (2) HK1221644A1 (hr)
HR (1) HRP20190405T1 (hr)
HU (1) HUE042607T2 (hr)
LT (1) LT3033101T (hr)
ME (1) ME03348B (hr)
MX (1) MX368508B (hr)
PL (1) PL3033101T3 (hr)
PT (1) PT3033101T (hr)
RS (1) RS58404B1 (hr)
RU (1) RU2676333C2 (hr)
SG (2) SG11201600481UA (hr)
SI (1) SI3033101T1 (hr)
TR (1) TR201903312T4 (hr)
WO (1) WO2015023504A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600483QA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP6803229B2 (ja) * 2013-08-12 2020-12-23 アストラゼネカ アクチボラグ ベンラリツマブによる喘息症状の改善方法
JP2016534996A (ja) * 2013-10-15 2016-11-10 メディミューン,エルエルシー ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
CN105611938A (zh) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
CA2936366A1 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−4およびペリオスチン
JP7174492B2 (ja) * 2017-01-04 2022-11-17 ウォルグ ファーマシューティカルズ (ハンジョウ) カンパニー,リミテッド S-アレスチンペプチドおよびその治療的使用
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP2068927B1 (en) * 2007-05-14 2015-10-21 MedImmune, LLC Methods of reducing eosinophil levels
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
EP2501228A4 (en) * 2009-11-18 2013-11-13 Medicinova Inc TREATMENT OF ACUTE ASTHMA CRISIS AND REDUCTION OF THE PROBABILITY OF HOSPITALIZATION OF PATIENTS WITH SUFFERING
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
SG11201600483QA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP6803229B2 (ja) 2013-08-12 2020-12-23 アストラゼネカ アクチボラグ ベンラリツマブによる喘息症状の改善方法

Also Published As

Publication number Publication date
JP2022120009A (ja) 2022-08-17
EP3033101A1 (en) 2016-06-22
CY1122132T1 (el) 2020-11-25
CA2918105A1 (en) 2015-02-19
SG11201600481UA (en) 2016-02-26
CA2918105C (en) 2023-02-28
EP3033101A4 (en) 2017-07-12
ME03348B (me) 2019-10-20
PT3033101T (pt) 2019-04-02
WO2015023504A1 (en) 2015-02-19
CN105451760A (zh) 2016-03-30
JP2020128375A (ja) 2020-08-27
HK1225302B (zh) 2017-09-08
TR201903312T4 (tr) 2019-04-22
ES2716906T3 (es) 2019-06-17
US9441037B2 (en) 2016-09-13
LT3033101T (lt) 2019-03-25
US20150044202A1 (en) 2015-02-12
JP2016527324A (ja) 2016-09-08
AU2014306956A1 (en) 2016-02-04
RU2016108723A3 (hr) 2018-06-18
HUE042607T2 (hu) 2019-07-29
EP3033101B1 (en) 2018-12-19
AU2020201327A1 (en) 2020-03-12
US20170198049A1 (en) 2017-07-13
DK3033101T3 (en) 2019-04-08
KR20160042121A (ko) 2016-04-18
BR112016002401A2 (pt) 2017-09-12
WO2015023504A8 (en) 2015-09-24
JP6746495B2 (ja) 2020-08-26
HK1221644A1 (zh) 2017-06-09
SI3033101T1 (sl) 2019-04-30
AU2014306956B2 (en) 2019-11-21
BR112016002401A8 (pt) 2018-06-12
KR102390714B1 (ko) 2022-04-26
RU2676333C2 (ru) 2018-12-28
RS58404B1 (sr) 2019-04-30
SG10202005560UA (en) 2020-07-29
PL3033101T3 (pl) 2019-06-28
MX2016001383A (es) 2016-08-03
RU2016108723A (ru) 2017-09-19
KR20220057637A (ko) 2022-05-09
MX368508B (es) 2019-10-07
CN111588848A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
HRP20190405T1 (hr) Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba
IL240215A0 (en) Methods for the purification of messenger RNA
HK1216429A1 (zh) 用於純化芳基硫酸酯酶 的方法
EP2968375A4 (en) PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS
HK1225303A1 (zh) 使用貝那利珠單抗改善哮喘症狀的方法
ZA201507475B (en) Method for the treatment of gas
IL237862A0 (en) Methods to reduce the formation of scale
HK1220969A1 (zh) 用於合成伊立替康的方法
GB201301125D0 (en) Methods for improving the efficency of gene targeting
EP2975005A4 (en) METHOD FOR PRODUCING A SUBSTITUTE
EP2964773A4 (en) milling
HK1216419A1 (zh) 合成方法
GB201316400D0 (en) Methods, compositions and kits for preparing sequencing library
GB201319952D0 (en) Methods of isolating ions
SG10201701021XA (en) Method of synthesis
GB201308949D0 (en) Compositions and methods for reducing methane production